Actively Recruiting
Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia
Led by Tufts Medical Center · Updated on 2026-04-06
60
Participants Needed
1
Research Sites
106 weeks
Total Duration
On this page
Sponsors
T
Tufts Medical Center
Lead Sponsor
N
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if veverimer will reduce urinary net acid excretion leading to reduced bone resorption in healthy adults with osteopenia. The main questions it aims to answer are: * How much does each dose of veverimer (vs. placebo) reduce 24-hr urinary net acid excretion. * Describe the safety of veverimer based on changes in serum bicarbonate and potassium. * Assess the changes in bone resorption. * Assess the changes in bone formation. * Explore the effect of veverimer on physical performance. Participants will: * Take veverimer or placebo every day or every other day for 8 weeks * Visit the clinic a total of 8 times (including screening) for checkups and testing * Keep a medication diary tracking each day they take the study drug
CONDITIONS
Official Title
Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults age 50 years and older living in the community
- Men must be sterile or use contraception throughout the study
- Women must be postmenopausal with no menstrual periods in the last 5 years
- Osteopenia defined by bone mineral density T-score between -1 and -2.5 at spine or hip
- Usual diet with acid load based on a validated questionnaire
- Estimated glomerular filtration rate (eGFR) of 45 ml/min or higher
- Agreement not to change exercise, medication, supplement use, or eating habits during the study
- Agreement not to use antacids during the study
- Agreement not to intentionally change weight during the study
You will not qualify if you...
- Normal bone mineral density or osteoporosis by T-score
- Respiratory illness in the last month
- Chronic obstructive pulmonary disease (COPD)
- Asthma
- Nausea or vomiting in the last month
- Difficulty swallowing (dysphagia)
- Malabsorption conditions
- Inflammatory bowel disease
- Chronic diarrhea or constipation
- Insulin-dependent diabetes or fasting glucose over 125 mg/dl
- Untreated thyroid disease
- Cirrhosis
- Current unstable heart disease
- Cancer (except non-melanoma skin cancer) or cancer treatment in the last year
- Alcohol use over 2 drinks per day
- Cognitive impairment preventing informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tufts Medical Center
Boston, Massachusetts, United States, 02111
Actively Recruiting
Research Team
E
Elise Danico, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here